Invention Grant
- Patent Title: Anti-CD277 antibodies
-
Application No.: US16282733Application Date: 2019-02-22
-
Publication No.: US10716838B2Publication Date: 2020-07-21
- Inventor: Daniel Olive , Marc Bonneville , Emmanuel Scotet , Christelle Harly , Yves Guillaume
- Applicant: Daniel Olive , Marc Bonneville , Emmanuel Scotet , Christelle Harly , Yves Guillaume
- Applicant Address: FR Paris FR Marseilles FR Marseilles FR Nantes FR Paris
- Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE),INSTITUT JEAN PAOLI & IRENE CALMETTES,UNIVERSITE D'AIX MARSEILLE,UNIVERSITE DE NANTES,CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
- Current Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE),INSTITUT JEAN PAOLI & IRENE CALMETTES,UNIVERSITE D'AIX MARSEILLE,UNIVERSITE DE NANTES,CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
- Current Assignee Address: FR Paris FR Marseilles FR Marseilles FR Nantes FR Paris
- Agency: W&C IP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@5ff93559
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; A61K39/00
Abstract:
Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vγ9/Vδ2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.
Public/Granted literature
- US20190201513A1 ANTI-CD277 ANTIBODIES AND USES THEREOF Public/Granted day:2019-07-04
Information query
